NASDAQ:MGTX - MeiraGTx Stock Price, Forecast & News

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

MeiraGTx Holdings PLC (NASDAQ:MGTX) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.53) by $0.23. The business earned $3.58 million during the quarter. View MeiraGTx's Earnings History.

MeiraGTx is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for MeiraGTx.

3 Wall Street analysts have issued 1 year target prices for MeiraGTx's shares. Their forecasts range from $30.00 to $45.00. On average, they anticipate MeiraGTx's stock price to reach $38.33 in the next year. This suggests a possible upside of 109.2% from the stock's current price. View Analyst Price Targets for MeiraGTx.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MeiraGTx.

Press coverage about MGTX stock has trended somewhat negative on Saturday, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MeiraGTx earned a daily sentiment score of -1.9 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for MeiraGTx.

MeiraGTx saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 841,500 shares, an increase of 11.4% from the December 31st total of 755,700 shares. Based on an average daily volume of 156,600 shares, the short-interest ratio is presently 5.4 days. Currently, 3.2% of the company's shares are sold short. View MeiraGTx's Current Options Chain.

Some companies that are related to MeiraGTx include Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Bill.com (RVMD), Cortexyme (CRTX), Coherus Biosciences (CHRS), SpringWorks Therapeutics (SWTX), Beam Therapeutics (BEAM), I-Mab (BDTX), Editas Medicine (EDIT), NanoString Technologies (NSTG), Orchard Therapeutics (ORTX), BAVARIAN NORDIC/S (BVNRY) and Twist Bioscience (TWST).

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Crispr Therapeutics (CRSP), Kadmon (KDMN), InVitae (NVTA), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Fate Therapeutics (FATE), Galmed Pharmaceuticals (GLMD), Intercept Pharmaceuticals (ICPT) and Inovio Pharmaceuticals (INO).

(MGTX) raised $75 million in an initial public offering (IPO) on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

MeiraGTx's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (0.93%), Alyeska Investment Group L.P. (0.91%), Rhenman & Partners Asset Management AB (0.52%), Geode Capital Management LLC (0.33%), Sectoral Asset Management Inc (0.26%) and Schonfeld Strategic Advisors LLC (0.24%). Company insiders that own MeiraGTx stock include Alexandria Forbes, Life Sciences Maste Perceptive, Nicole Seligman and Richard Giroux. View Institutional Ownership Trends for MeiraGTx.

MGTX stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Panagora Asset Management Inc., Alyeska Investment Group L.P., Renaissance Technologies LLC, Russell Investments Group Ltd., Goldman Sachs Group Inc. and Meeder Asset Management Inc.. Company insiders that have sold MeiraGTx company stock in the last year include Alexandria Forbes and Richard Giroux. View Insider Buying and Selling for MeiraGTx.

MGTX stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Parkman Healthcare Partners LLC, California Public Employees Retirement System, Acadian Asset Management LLC, Schonfeld Strategic Advisors LLC, Algert Global LLC, State Street Corp and Claraphi Advisory Network LLC. Company insiders that have bought MeiraGTx stock in the last two years include Life Sciences Maste Perceptive and Nicole Seligman. View Insider Buying and Selling for MeiraGTx.

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MGTX stock can currently be purchased for approximately $18.32.

MeiraGTx has a market capitalization of $669.96 million. The company earns $-82,870,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. MeiraGTx employs 68 workers across the globe.View Additional Information About MeiraGTx.

The official website for MeiraGTx is http://www.meiragtx.com/.

MeiraGTx's mailing address is 450 East 29thStreet 15thFloor, NEW YORK NY, 10016. The company can be reached via phone at 646-860-7985 or via email at [email protected]